In this week’s #AskDrDurie myeloma expert Dr. Brian G.M. Durie discusses monoclonal gammopathy of undetermined significance (MGUS).
The BOTTOM LINE: Monoclonal gammopathy of undetermined significance (MGUS) is a precursor to myeloma, but the chance of progression is only 1% per year.
_______________
Improving Lives | Finding the Cure
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: [ Ссылка ]
Visit our website at: [ Ссылка ]
Find us online:
Facebook: @myeloma | [ Ссылка ]
Twitter: @IMFMyeloma | [ Ссылка ]
Instagram: @imfmyeloma | [ Ссылка ]
LinkedIn: [ Ссылка ]
Support the IMF | Donate Now! [ Ссылка ]
Category
Nonprofits & Activism
License
Standard YouTube License
In most cases, captions are autogenerated by YouTube.
What is MGUS?
Теги
myelomamultiple myelomacancerbone marrow cancercancer treatmentcancer researchbone diseasedr brian duriebone marrowmultiple myeloma cancerbone cancerblood cancerblood plasma cancerblood cancer researchcancer research foundationmyeloma treatmentmgusrelapserefractoryinternational myeloma foundationmultiple myeloma foundationcure trialsmyeloma cure trialsBlack Swan Researchmonoclonal gammopathy of undetermined significanceMGUS